{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T14:40:12Z","timestamp":1778942412154,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Convalescent plasma (CP) transfusion has been indicated as a promising therapy in the treatment for other emerging viral infections. However, the quality control of CP and individual variation in patients in different studies make it rather difficult to evaluate the efficacy and risk of CP therapy for coronavirus disease 2019 (COVID-19). We aimed to explore the potential efficacy of CP therapy, and to assess the possible factors associated with its efficacy. We enrolled eight critical or severe COVID-19 patients from four centers. Each patient was transfused with 200\u2013400\u2009mL of CP from seven recovered donors. The primary indicators for clinical efficacy assessment were the changes of clinical symptoms, laboratory parameters, and radiological image after CP transfusion. CP donors had a wide range of antibody levels measured by serology tests which were to some degree correlated with the neutralizing antibody (NAb) level. No adverse events were observed during and after CP transfusion. Following CP transfusion, six out of eight patients showed improved oxygen support status; chest CT indicated varying degrees of absorption of pulmonary lesions in six patients within 8 days; the viral load was decreased to a negative level in five patients who had the previous viremia; other laboratory parameters also tended to improve, including increased lymphocyte counts, decreased C-reactive protein, procalcitonin, and indicators for liver function. The clinical efficacy might be associated with CP transfusion time, transfused dose, and the NAb levels of CP. This study indicated that CP might be a potential therapy for severe patients with COVID-19.<\/jats:p>","DOI":"10.1038\/s41392-020-00329-x","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T22:03:03Z","timestamp":1602021783000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series"],"prefix":"10.1038","volume":"5","author":[{"given":"Hao","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingmin","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haoyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-4551","authenticated-orcid":false,"given":"Jiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changlong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haibo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yishan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-0108","authenticated-orcid":false,"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanming","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"329_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"329_CR2","unstructured":"WHO. Novel coronavirus (COVID-19) situation. https:\/\/who.sprinklr.com (2020)."},{"key":"329_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong, L., Hu, S. & Gao, J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Disco. Ther. 14, 58\u201360 (2020).","journal-title":"Drug Disco. Ther."},{"key":"329_CR4","doi-asserted-by":"publisher","unstructured":"Barlow, A. et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. https:\/\/doi.org\/10.1002\/phar.2398 (2020).","DOI":"10.1002\/phar.2398"},{"key":"329_CR5","doi-asserted-by":"publisher","unstructured":"Grein, J. et al. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2007016 (2020).","DOI":"10.1056\/NEJMoa2007016"},{"key":"329_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1473-3099(20)30141-9","volume":"20","author":"L Chen","year":"2020","unstructured":"Chen, L., Xiong, J., Bao, L. & Shi, Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 20, 398\u2013400 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"329_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","volume":"24","author":"Y Cheng","year":"2005","unstructured":"Cheng, Y. et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis. 24, 44\u201346 (2005).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"329_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/infdis\/jiu396","volume":"211","author":"J Mair-Jenkins","year":"2015","unstructured":"Mair-Jenkins, J. et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J. Infect. Dis. 211, 80\u201390 (2015).","journal-title":"J. Infect. Dis."},{"key":"329_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/cid\/ciq106","volume":"52","author":"IF Hung","year":"2011","unstructured":"Hung, I. F. et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin. Infect. Dis. 52, 447\u2013456 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"329_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3851\/IMP3243","volume":"23","author":"JH Ko","year":"2018","unstructured":"Ko, J. H. et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir. Ther. 23, 617\u2013622 (2018).","journal-title":"Antivir. Ther."},{"key":"329_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002985","volume":"3","author":"H Yu","year":"2008","unstructured":"Yu, H. et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PloS ONE 3, e2985 (2008).","journal-title":"PloS ONE"},{"key":"329_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1511812","volume":"374","author":"J van Griensven","year":"2016","unstructured":"van Griensven, J. et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N. Engl. J. Med. 374, 33\u201342 (2016).","journal-title":"N. Engl. J. Med"},{"key":"329_CR13","doi-asserted-by":"publisher","unstructured":"Shen, C. et al. Treatment of 5 critically Ill patients With COVID-19 with convalescent plasma. JAMA. https:\/\/doi.org\/10.1001\/jama.2020.4783 (2020).","DOI":"10.1001\/jama.2020.4783"},{"key":"329_CR14","doi-asserted-by":"publisher","unstructured":"Duan, K. et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA. https:\/\/doi.org\/10.1073\/pnas.2004168117 (2020).","DOI":"10.1073\/pnas.2004168117"},{"key":"329_CR15","doi-asserted-by":"publisher","unstructured":"Zhang, B. et al. Treatment with convalescent plasma for critically Ill patients with SARS-CoV-2 infection. Chest. https:\/\/doi.org\/10.1016\/j.chest.2020.03.039 (2020).","DOI":"10.1016\/j.chest.2020.03.039"},{"key":"329_CR16","doi-asserted-by":"publisher","unstructured":"Ye, M. et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.25882 (2020).","DOI":"10.1002\/jmv.25882"},{"key":"329_CR17","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e149","volume":"35","author":"JY Ahn","year":"2020","unstructured":"Ahn, J. Y. et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J. Korean Med. Sci. 35, e149 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"329_CR18","unstructured":"WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected: interim guidance. https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (2020)."},{"key":"329_CR19","unstructured":"China NHCo. Guideline for diagnosis and treatment for novel coronavirus pneumonia (sixth edition). http:\/\/www.nhc.gov.cn\/xcs\/zhengcwj\/202002\/8334a8326dd94d329df351d7da8aefc2.shtml (2020)."},{"key":"329_CR20","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","volume":"9","author":"J Nie","year":"2020","unstructured":"Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg. Microbes Infect. 9, 680\u2013686 (2020).","journal-title":"Emerg. Microbes Infect."},{"key":"329_CR21","doi-asserted-by":"publisher","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","volume":"145","author":"TC Luke","year":"2006","unstructured":"Luke, T. C., Kilbane, E. M., Jackson, J. L. & Hoffman, S. L. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann. Intern. Med. 145, 599\u2013609 (2006).","journal-title":"Ann. Intern. Med."},{"key":"329_CR22","doi-asserted-by":"publisher","unstructured":"Rajendran, K. et al. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.25961 (2020).","DOI":"10.1002\/jmv.25961"},{"key":"329_CR23","doi-asserted-by":"publisher","unstructured":"Bloch, E. M. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J. Clin. Invest. https:\/\/doi.org\/10.1172\/JCI138745 (2020).","DOI":"10.1172\/JCI138745"},{"key":"329_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam5752","volume":"9","author":"C Shen","year":"2017","unstructured":"Shen, C. et al. A multimechanistic antibody targeting the receptor binding site potently cross-protects against influenza B viruses. Sci. Transl. Med 9, eaam5752 (2017).","journal-title":"Sci. Transl. Med"},{"key":"329_CR25","doi-asserted-by":"publisher","unstructured":"Luchsinger, L. L. et al. Serological analysis of New York City COVID19 convalescent plasma donors. medRxiv. Preprint at https:\/\/doi.org\/10.1101\/2020.06.08.20124792 (2020).","DOI":"10.1101\/2020.06.08.20124792"},{"key":"329_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41577-020-0308-3","volume":"20","author":"X Cao","year":"2020","unstructured":"Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 20, 269\u2013270 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"329_CR27","doi-asserted-by":"publisher","unstructured":"Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa344 (2020).","DOI":"10.1093\/cid\/ciaa344"},{"key":"329_CR28","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/infdis\/jiaa228","volume":"222","author":"QL Zeng","year":"2020","unstructured":"Zeng, Q. L. et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J. Infect. Dis. 222, 38\u201343 (2020).","journal-title":"J. Infect. Dis."},{"key":"329_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368, 473\u2013474 (2020).","journal-title":"Science"},{"key":"329_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"52","author":"T Hirano","year":"2020","unstructured":"Hirano, T. & Murakami, M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity 52, 731\u2013733 (2020).","journal-title":"Immunity"},{"key":"329_CR31","unstructured":"FDA. FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, Another achievement in administration\u2019s fight against pandemic, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment."},{"key":"329_CR32","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang, C., Wu, Z., Li, J. W., Zhao, H. & Wang, G. Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J. Antimicrob. Agents 55, 105954 (2020).","journal-title":"Int J. Antimicrob. Agents"},{"key":"329_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41392-020-0148-4","volume":"5","author":"L Tan","year":"2020","unstructured":"Tan, L. et al. Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct. Target Ther. 5, 33 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"329_CR34","doi-asserted-by":"publisher","unstructured":"Tiberghien, P. et al. Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how? Vox Sang. https:\/\/doi.org\/10.1111\/vox.12926 (2020).","DOI":"10.1111\/vox.12926"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00329-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00329-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T13:36:10Z","timestamp":1670247370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-020-00329-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1038\/s41392-020-00329-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}